Friedreich’s ataxia (FA) is a rare, autosomal recessive neurodegenerative disease whose natural history and clinical characterization have made significant progress in recent decades. Nevertheless, there is still a lack of sensitive, objective biomarkers that both reliably reflect disease progression and are practicable for clinical studies. The TRACK-FA study, the largest multicenter, multimodal neuroimaging study in FA to date, is now making a decisive contribution. It shows that structural and functional imaging markers not only detect disease-relevant changes, but also correlate with clinical scales. This opens up new avenues for more precise diagnostics, the development of therapies and the shortening of study durations.
Autoren
- Tanja Schliebe
Publikation
- InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
You May Also Like
- From symptom to diagnosis
Gynecomastia and Adipomastia
- Plastic surgery and reconstructive microsurgery for DFS
Functional limb preservation between infection control, vascular medicine and resurfacing
- SURPASS-CVOT
Tirzepatide versus Dulaglutide in T2D with ASCVD
- Secondary prevention after ACS: individually optimized lipid management
Trend towards early combination therapy and new strategies for lowering Lp(a)
- Pediatric Brain Tumors
Psychiatry versus Neuro-Oncology: Diagnostic Pitfalls
- What the latest studies on the entire EF spectrum mean for clinical practice
Heart Failure – The 2026 Evidence Update
- Acute ischemic stroke
Alteplase and Tenecteplase Are on the Same Level
- CKD in People with Type 2 Diabetes: Evidence-Based, Optimized Treatment